The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of PF-06473871 in normal healthy adults.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
32
80 mg of PF-06473871 or placebo
160 mg of PF-06473871 or placebo
320 mg of PF-06473871 or placebo
Pfizer Clinical Research Unit
Brussels, Belgium
Incidence of Adverse events
will be reviewed and summarized on an ongoing basis during the study to evaluate the safety of subjects
Time frame: 6 weeks
ECGs
will be reviewed and summarized on an ongoing basis during the study to evaluate the safety of subjects
Time frame: 6 weeks
Blood pressure
will be reviewed and summarized on an ongoing basis during the study to evaluate the safety of subjects
Time frame: 6 weeks
pulse rate
will be reviewed and summarized on an ongoing basis during the study to evaluate the safety of subjects
Time frame: 6 weeks
Injection siter reaction
The number and percentage of subjects that experienced injection site reactions will be analyzed.
Time frame: 6 weeks
number of subjects with adverse events
will be reviewed and summarized on an ongoing basis during the study to evaluate the safety of subjects
Time frame: 6 weeks
severity of adverse events
will be reviewed and summarized on an ongoing basis during the study to evaluate the safety of subjects
Time frame: 6 weeks
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
480 mg of PF-06473871 or placebo
Area under the Concentration-Time Curve (AUC)
AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.
Time frame: 6 weeks
Maximum Observed Plasma Concentration (Cmax)
Time frame: 6 weeks